A 39-year-old man with HIV-associated lipodystrophy.
Fuller. Jon J
Key Findings
- HIV can cause both fat buildup (lipohypertrophy) and fat loss (lipoatrophy).
- These changes are linked to insulin resistance, high lipids, and can be psychologically upsetting.
- Certain HIV drugs (stavudine, zidovudine) are tied to lipoatrophy, and body‑shape changes may reduce patients’ willingness to stay on therapy.
Practical Outcomes
- This report doesn’t provide any direct guidance on tesamorelin use or dosing for biohackers. It simply underscores that body‑composition issues in HIV need careful monitoring and support, but no actionable protocol is offered.
Summary
The abstract describes a 39‑year‑old man with HIV‑related changes in body fat that cause him distress, but it doesn’t discuss tesamorelin or give any tips for using it. It mainly highlights how lipodystrophy can affect mood and treatment adherence.
Abstract
Human immunodeficiency virus (HIV)-associated lipodystrophy refers to fat accumulation, also known as lipohypertrophy, and fat wasting, also known as lipoatrophy. Both conditions can be very disturbing to patients and have been associated with metabolic disturbances such as insulin resistance and hyperlipidemias. The prevalence of HIV-associated lipodystrophy ranges from 6% to 69% in the medical literature. Although no clear associations have been made between specific drugs and HIV lipohypertrophy, stavudine and zidovudine have been implicated in the development of HIV lipoatrophy. The case of Mr B, a 39-year-old man with HIV-associated lipodystrophy whose facial changes are a cause of significant distress, highlights the need for clinicians to be attuned to the psychological impact that lipodystrophy can have on patients, especially because it may serve as a disincentive to adherence to antiretroviral drug regimens, resulting in an increased risk of developing viral resistance.
Study Information
pubmed
2008
2008-08-03T00:00:00.000Z
10.1001/jama.300.5.jrr80007
15
134